By Zhu Wenjun

On 29 June, Merck Investment (China) Co., Ltd. and Nantong Economic& Technological Development Area signed a cooperation agreement, planned to invest about 70 million euros to build Merck Life Science Center high purity reagent production base.

Since it started to plan in Nantong, Merck has invested over 2.7 billion yuan in total, which accounts for more than half of its investment in China. In 2022, the company realized an output value of about 5.8 billion yuan, there was an increase of over 30%. The high purity reagent production base is planned to be in operation in 2026. It has broad application space in product quality control and check including pharmaceutical, food and beverage fields, and will promote the improvement and upgrading of biological medicine industrial chain of Nantong effectively.